SK16192000A3 - Protilátkový proteín, nukleotidová sekvencia kódujúca proteín, rekombinantný dna vektor, hostiteľská bunka, spôsob jeho výroby, farmaceutický prostriedok s jeho obsahom a jeho použitie - Google Patents

Protilátkový proteín, nukleotidová sekvencia kódujúca proteín, rekombinantný dna vektor, hostiteľská bunka, spôsob jeho výroby, farmaceutický prostriedok s jeho obsahom a jeho použitie Download PDF

Info

Publication number
SK16192000A3
SK16192000A3 SK1619-2000A SK16192000A SK16192000A3 SK 16192000 A3 SK16192000 A3 SK 16192000A3 SK 16192000 A SK16192000 A SK 16192000A SK 16192000 A3 SK16192000 A3 SK 16192000A3
Authority
SK
Slovakia
Prior art keywords
antibody
antibody protein
cancer
human
protein
Prior art date
Application number
SK1619-2000A
Other languages
English (en)
Slovak (sk)
Inventor
John Edward Park
Pilar Garin-Chesa
Uwe Bamberger
Wolfgang J. Rettig
Olivier L�Ger
Jose Wlliam Saldanha
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of SK16192000A3 publication Critical patent/SK16192000A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SK1619-2000A 1998-04-30 1999-04-22 Protilátkový proteín, nukleotidová sekvencia kódujúca proteín, rekombinantný dna vektor, hostiteľská bunka, spôsob jeho výroby, farmaceutický prostriedok s jeho obsahom a jeho použitie SK16192000A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98107925A EP0953639A1 (en) 1998-04-30 1998-04-30 FAPalpha-specific antibody with improved producibility
PCT/EP1999/002711 WO1999057151A2 (en) 1998-04-30 1999-04-22 FAP α-SPECIFIC ANTIBODY WITH IMPROVED PRODUCIBILITY

Publications (1)

Publication Number Publication Date
SK16192000A3 true SK16192000A3 (sk) 2001-04-09

Family

ID=8231860

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1619-2000A SK16192000A3 (sk) 1998-04-30 1999-04-22 Protilátkový proteín, nukleotidová sekvencia kódujúca proteín, rekombinantný dna vektor, hostiteľská bunka, spôsob jeho výroby, farmaceutický prostriedok s jeho obsahom a jeho použitie

Country Status (27)

Country Link
EP (2) EP0953639A1 (et)
JP (1) JP4421779B2 (et)
KR (1) KR100580936B1 (et)
CN (1) CN1303430A (et)
AR (1) AR016243A1 (et)
AT (1) ATE356873T1 (et)
AU (1) AU760305B2 (et)
BG (1) BG65034B1 (et)
BR (1) BR9910577A (et)
CA (1) CA2327586C (et)
CO (1) CO5050255A1 (et)
DE (1) DE69935516T2 (et)
EA (1) EA005401B1 (et)
EE (1) EE200000642A (et)
ES (1) ES2283114T3 (et)
HU (1) HUP0101501A3 (et)
ID (1) ID26555A (et)
IL (1) IL138701A0 (et)
NO (1) NO20005412L (et)
NZ (1) NZ508456A (et)
PL (1) PL358087A1 (et)
SK (1) SK16192000A3 (et)
TR (1) TR200003181T2 (et)
UA (1) UA73276C2 (et)
WO (1) WO1999057151A2 (et)
YU (1) YU66300A (et)
ZA (1) ZA200005506B (et)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
EP1268550A2 (en) * 2000-03-17 2003-01-02 Boehringer Ingelheim Pharma KG Human fap-alpha-specific antibodies
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
EP2365004B1 (en) * 2002-06-21 2016-01-06 Johns Hopkins University School of Medicine Membrane associated tumor endothelium markers
WO2004016750A2 (en) * 2002-08-14 2004-02-26 Macrogenics, Inc. FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1594955B1 (en) * 2003-02-14 2012-04-11 Biogen Idec MA Inc. An expression cassette and vector for transient or stable expression of exogenous molecules
JP2007536932A (ja) 2004-05-10 2007-12-20 マクロジェニクス，インコーポレーテッド ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
HUE029465T2 (en) 2005-08-10 2017-02-28 Macrogenics Inc Identification and engineering of antibodies with variant Fc regions and methods of using same
US10155816B2 (en) * 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
EP1806365A1 (en) * 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
CA2660592C (en) 2006-05-26 2016-07-12 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
AU2007281876B2 (en) 2006-06-26 2013-09-05 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
AU2008205512B2 (en) 2007-01-16 2014-06-12 Abbvie Inc. Methods for treating psoriasis
NZ598881A (en) 2007-03-29 2013-11-29 Abbvie Inc Crystalline anti-human il-12 antibodies
EP2185591B1 (en) * 2007-08-20 2014-05-14 Glaxo Group Limited Production method
EP2071337A1 (en) * 2007-12-10 2009-06-17 F.Hoffmann-La Roche Ag Seprase as a marker for cancer
CN101896817A (zh) * 2007-12-10 2010-11-24 霍夫曼-拉罗奇有限公司 用于结直肠癌的标记物组
CN101896818B (zh) 2007-12-10 2016-01-20 霍夫曼-拉罗奇有限公司 作为癌症的标记物的Seprase
BRPI0908715A2 (pt) 2008-03-18 2016-05-03 Abbott Lab métodos para tratamento da psoríase
JP5785490B2 (ja) 2008-04-02 2015-09-30 マクロジェニクス，インコーポレーテッド Ｂｃｒ複合体特異的抗体およびその使用方法
HUE029925T2 (en) 2008-04-02 2017-04-28 Macrogenics Inc HER2 / neu-specific antibodies and methods using them
AU2010291927A1 (en) 2009-09-14 2012-04-12 AbbVie Deutschland GmbH & Co. KG Methods for treating psoriasis
AU2010303415B2 (en) 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
SG187746A1 (en) * 2010-08-13 2013-03-28 Roche Glycart Ag Anti-fap antibodies and methods of use
SG10201912092VA (en) 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
HUE029139T2 (hu) 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
JP6498600B2 (ja) 2012-06-08 2019-04-10 ストロ バイオファーマ インコーポレーテッド 部位特異的な非天然アミノ酸残基を含む抗体、その調製方法、及びその使用方法
EP2863955B1 (en) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
EP3122775B1 (en) * 2014-03-26 2019-11-13 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
CN105646710B (zh) * 2014-11-17 2020-08-25 四川科伦博泰生物医药股份有限公司 一种全人源化抗vegfr-2单克隆抗体及其制备方法
BR112018002570A2 (pt) 2015-10-02 2018-10-16 Hoffmann La Roche molécula de ligação ao antígeno biespecífica, anticorpo biespecífico, polinucleotídeos, anticorpo que se liga especificamente ao ox40, composição farmacêutica e método para inibir o crescimento de células tumorais em um indivíduo
MX2018009085A (es) * 2016-01-27 2019-05-09 Sutro Biopharma Inc Conjugados de anticuerpos anti-cd74, composiciones que comprenden conjugados de anticuerpos anti-cd74 y metodos de uso de congujados de anticuerpos anti-cd74.
CA3020864A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
CN109983121A (zh) 2016-06-30 2019-07-05 昂克诺斯公司 治疗性多肽的假型化溶瘤病毒递送
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
US20200237936A1 (en) * 2016-12-14 2020-07-30 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
CN110526991A (zh) * 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 靶向fap的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
CN110526979A (zh) * 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 靶向fap的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
CN109053893B (zh) * 2018-08-15 2021-03-30 智享生物(苏州)有限公司 一种抗d-二聚体单克隆抗体及其制备方法
CN110882385B (zh) * 2018-09-07 2021-07-09 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗肿瘤中的用途
CN114853908B (zh) * 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
EP3763726A1 (en) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
WO2021005125A1 (en) 2019-07-08 2021-01-14 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
EP3997104A1 (en) 2019-07-08 2022-05-18 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
CN114206929B (zh) * 2019-09-03 2023-12-22 百奥泰生物制药股份有限公司 一种抗tigit免疫抑制剂及应用
CN113512116B (zh) * 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
KR102363980B1 (ko) * 2020-04-13 2022-02-15 전남대학교산학협력단 전이성 뇌종양의 진단 또는 예후 분석용 바이오마커 및 이를 이용한 진단방법
EP4143239A4 (en) * 2020-04-30 2024-10-02 I-Mab Biopharma Co., Ltd. PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-CD47 ANTIBODIES
CA3180665A1 (en) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
WO2022007283A1 (zh) * 2020-07-08 2022-01-13 深圳霁因生物医药转化研究院 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质
CN116390937A (zh) * 2020-08-11 2023-07-04 治纳辅医药科技有限公司 一种包含il-12和抗cd20抗体的融合蛋白及其应用
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
EP4274835A1 (en) 2021-01-07 2023-11-15 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
WO2023031644A1 (en) 2021-08-31 2023-03-09 Full-Life Technologies Limited Anti-fibroblast activation protein (fap) single domain antibodies and uses thereof
CN118974258A (zh) * 2021-12-30 2024-11-15 乐普创一生物科技（上海）有限公司 抗fap-alpha的人源抗体
CN119604540A (zh) 2022-08-03 2025-03-11 南京维立志博生物科技股份有限公司 靶向FAP和TGFβ的抗体融合蛋白及其用途
CN120112308A (zh) 2022-10-07 2025-06-06 吉尼松公司 使用抗fap car-t细胞免疫治疗骨骼肌病
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
CN120309735A (zh) * 2024-01-15 2025-07-15 迈威(上海)生物科技股份有限公司 重组抗fap抗体及其应用
CN118496382B (zh) * 2024-05-22 2025-01-07 山东第一医科大学附属省立医院(山东省立医院) 一种靶向fap的嵌合抗原受体、car-t细胞及其在肝纤维化中的应用
CN118812715A (zh) * 2024-07-02 2024-10-22 国睿(广州)生物科技有限公司 一种靶向成纤维活化蛋白α的纳米抗体及其应用
CN119265201A (zh) * 2024-08-23 2025-01-07 中国人民解放军海军军医大学第一附属医院 编码基因、蛋白、表达il-15的nkg2dl-fap双靶点car-nk细胞及其构建方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059523A (en) * 1988-05-02 1991-10-22 Sloan-Kettering Institute For Cancer Research Cell-surface glycoproteins of human sarcomas
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU2782292A (en) * 1991-09-18 1993-04-27 Sloan-Kettering Institute For Cancer Research Activated stromal fibroblast-specific antibody, f19 and methods of using the same
ZA936260B (en) * 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
ATE219517T1 (de) * 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
AU716257B2 (en) * 1996-05-01 2000-02-24 Genitope Corporation Vaccines for treatment of lymphoma and leukemia

Also Published As

Publication number Publication date
BG65034B1 (bg) 2006-12-29
EP0953639A1 (en) 1999-11-03
ATE356873T1 (de) 2007-04-15
AU4032299A (en) 1999-11-23
EP1098979A2 (en) 2001-05-16
EA200001023A1 (ru) 2001-06-25
ID26555A (id) 2001-01-18
AU760305B2 (en) 2003-05-15
HUP0101501A2 (hu) 2001-08-28
AR016243A1 (es) 2001-06-20
ZA200005506B (en) 2002-05-14
CO5050255A1 (es) 2001-06-27
NZ508456A (en) 2004-03-26
ES2283114T3 (es) 2007-10-16
EP1098979B1 (en) 2007-03-14
EA005401B1 (ru) 2005-02-24
IL138701A0 (en) 2001-10-31
HUP0101501A3 (en) 2004-01-28
JP4421779B2 (ja) 2010-02-24
KR20010042826A (ko) 2001-05-25
PL358087A1 (en) 2004-08-09
NO20005412D0 (no) 2000-10-27
KR100580936B1 (ko) 2006-05-17
BG104828A (en) 2001-09-28
WO1999057151A3 (en) 2000-03-16
UA73276C2 (en) 2005-07-15
BR9910577A (pt) 2001-09-11
TR200003181T2 (tr) 2001-04-20
NO20005412L (no) 2000-12-06
EE200000642A (et) 2002-04-15
CN1303430A (zh) 2001-07-11
WO1999057151A2 (en) 1999-11-11
DE69935516T2 (de) 2008-01-31
YU66300A (sh) 2004-03-12
JP2002513556A (ja) 2002-05-14
DE69935516D1 (de) 2007-04-26
CA2327586C (en) 2013-02-26
CA2327586A1 (en) 1999-11-11

Similar Documents

Publication Publication Date Title
AU760305B2 (en) FAP alpha-specific antibody with improved producibility
US6455677B1 (en) FAPα-specific antibody with improved producibility
KR102613430B1 (ko) 인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
KR101169254B1 (ko) 종양질병 또는 면역결핍의 치료를 위한 인간화된 면역조절단일항체
US5969109A (en) Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
AU2016321244B2 (en) Treatment of retinitis pigmentosa using engineered meganucleases
ES2250105T3 (es) Anticuerpos policlonales humanos de animales transgenicos no humanos.
AU2016315703A1 (en) Chimeric AAV-anti-VEGF for treating cancer in canines
CN108135999B (zh) 针对狂犬病的人抗体及其用途
US12410240B2 (en) Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
SG175682A1 (en) Selection of human monoclonal antibodies by mammalian cell display
KR102102239B1 (ko) 유방암을 치료하기 위한 방법
KR20230019450A (ko) 캡슐화된 rna 레플리콘 및 사용 방법
JPS6269991A (ja) 牛下痢症ウイルス由来のワクチンと診断薬
CN113614234A (zh) 肝脏特异性诱导型启动子及其使用方法
KR20230058081A (ko) 인간 IgG1의 변형된 FC 영역과 적어도 하나의 이종 항원을 포함하는 폴리펩티드를 암호화하는 핵산
CA2269757A1 (en) Structure of secretory immunoglobulin a
KR20070084330A (ko) 가용성 ｚｃｙｔｏｒ21, 항-ｚｃｙｔｏｒ21 항체 및 결합파트너 및 염증에서의 사용방법
HK1035746A (en) FAPα-SPECIFIC ANTIBODY WITH IMPROVED PRODUCIBILITY
CN103998059A (zh) 用于中和狂犬病病毒的结合分子
CN116606373A (zh) 新型冠状病毒中和抗体及其用途
KR20100014279A (ko) 인간 엘디엘 수용체에 대한 단일클론항체
CN116457009A (zh) 编码包含人IgG1的经修饰的Fc区和至少一种异源抗原的多肽的核酸
HK40031291A (en) Methods of treating triple negative breast cancer and basal-like breast cancer using inhibitors against kidney associated 1 (kaag1) inhibitor
HK40062585A (en) Liver-specific inducible promoters and methods of use thereof